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Nuclear receptors undergo ligand-dependent
conformational changes that are required for
corepressor-coactivatorexchange,butwhether
there is an actual requirement for specific epige-
netic landmarks to impose ligand dependency
for gene activation remains unknown. Here we
report an unexpected and general strategy
that is based on the requirement for specific co-
horts of inhibitory histone methyltransferases
(HMTs) to impose gene-specific gatekeeper
functions that prevent unliganded nuclear re-
ceptors and other classes of regulated tran-
scription factors from binding to their target
gene promoters and causing constitutive gene
activation in the absence of stimulating signals.
This strategy, based at least in part on an HMT-
dependent inhibitory histone code, imposes a
requirement for specific histone demethylases,
including LSD1, to permit ligand- and signal-
dependent activation of regulated gene expres-
sion. These events link an inhibitorymethylation
component of the histone code to a broadly
used strategy that circumvents pathological
constitutive gene induction by physiologically
regulated transcription factors.
INTRODUCTION
Ligand-dependent activation of large transcriptional gene
programs that are simultaneously regulated by nuclear re-
ceptors provides critical strategies for development and
homeostasis of all metazoans, and its misregulation is as-
sociated with many types of disease. Regulated transcrip-tion by nuclear receptors is mediated by ligands binding
to the C-terminal domain, thus causing conformational
changes; these include a change in the position of the
so-called AF2 helix, which favors association with specific
coactivator complexes and functional conversion of the
receptor to an activator (reviewed in Rosenfeld et al.,
2006). Thus, when unliganded, nuclear receptors, such
as the thyroid hormone (T3) and the retinoid acid (RA) re-
ceptors, act as repressors primarily by recruiting specific
corepressor complexes via the ‘‘CoRNR’’ domain (Horlein
et al., 1995; Chen and Evans, 1995; Heinzel et al., 1997;
Privalsky, 2004), but, when liganded, they are functionally
converted to activators by recruiting coactivator com-
plexes. In addition, for many nuclear receptors, such as
estrogen receptor a (ERa) and androgen receptor (AR),
other signaling pathways can cause similar recruitment
of coactivators and the consequent functional conversion
to transcriptional activators even in the absence of ligand
(Culig et al., 1994; Nazareth and Weigel, 1996; Zwijsen
et al., 1997; Rogatsky et al., 1999; Ueda et al., 2002;
Ogawa et al., 2004; Kim et al., 2005). Therefore, it is of par-
ticular interest to further explore the linkage between the
recruitment of nuclear receptors and the coregulatory
complexes that underlie ligand-dependent and -indepen-
dent activation of transcriptional programs.
Most coregulatory complexes exhibit a diversity of en-
zymatic activities that can be divided into two generic
classes: enzymes capable of remodeling the structure of
the nucleosome in an ATP-dependent manner and en-
zymes capable of covalently modifying histone tails; this
latter group includes acetylating and deacetylating activi-
ties (HATs and HDACs); methylating and demethylating
activities (HMTs and HDMs); kinases and phosphatases;
poly(ADP)ribosylases; and ubiquitin and SUMO ligases
(reviewed in Narlikar et al., 2002; Rosenfeld et al., 2006).
The histone code model (Strahl and Allis, 2000; Jenuwein
and Allis, 2001) suggests that serial posttranslational
histone modifications, such as acetylation, methylation,Cell 128, 505–518, February 9, 2007 ª2007 Elsevier Inc. 505
phosphorylation, and sumoylation, correlate with the spe-
cific activated or repressed status of the promoter (re-
viewed in Fischle et al., 2003; Peterson and Laniel, 2004;
Margueron et al., 2005). Presumably, the deposition and
removal of these marks correspond to a large variety of
coregulatory complexes that act in a sequential and com-
binatorial fashion to ultimately determine spatial and tem-
poral control of gene expression (reviewed in McKenna
and O’Malley, 2002; Rosenfeld et al., 2006). One of these
marks, the histone lysine methylation, was initially consid-
ered as a permanent posttranslational modification that
exerts long-term epigenetic memory (reviewed in Kouzar-
ides, 2002; Lachner and Jenuwein, 2002). However, re-
cent data demonstrating the existence of lysine demethy-
lase activities have dramatically challenged this model
(Shi et al., 2004; Metzger et al., 2005; Tsukada et al.,
2006; Yamane et al., 2006; Whetstine et al., 2006).
Histone lysine methylation has been extensively linked
to both gene activation and gene repression events in
euchromatic and heterochromatic regions (reviewed in
Lachner and Jenuwein, 2002; Martin and Zhang, 2005).
A large number of SET-domain-containing enzymes, in-
cluding RIZ1, ESET, Eu-HMTase1, G9a, Suv39h1/h2,
MLL1, and others, have been shown to transfer methyl
groups to histones and to transcription factors; in particu-
lar, this has been shown at multiple lysine residues in his-
tones, including H3-K4, K9, K27, K36, K79, H4-K20, and
H1-K26, all of which have been reported in most cases
to be mono-, di-, and trimethylated (reviewed in Martin
and Zhang, 2005). It has been proposed that methyl
groups may act as binding sites for a wide range of chro-
matin proteins, including the repressive heterochromatin
protein 1 (HP1), which has been reported to bind methyl
groups on histone H3 at lysine 9 (H3-K9; Nielsen et al.,
2001), as well as the transcriptional activator WDR5 and
the ATP-dependent chromatin-remodeling protein CDH1,
which have been reported to bind methyl groups on H3
at lysine 4 (H3-K4; Wysocka et al., 2005; Dou et al.,
2005; Flanagan et al., 2005).
Recently, a CoREST corepressor complex component
(Tong et al., 1998; Andres et al., 1999; Ballas et al.,
2001; Humphrey et al., 2001; You et al., 2001; Hakimi
et al., 2002, 2003; Lunyak et al., 2002; Shi et al., 2003)
known as LSD1/BHC110/KIAA0601/p110b was identified
as the first histone lysine demethylase, which is involved in
mediating neuron-restrictive silencing factor (NRSF)/
REST-dependent repression of neuronal genes in non-
neuronal cells (Shi et al., 2004, 2005). In vitro, LSD1 specif-
ically demethylates mono- and dimethylated H3-K4,
which, in vivo, has been suggested to mediate gene re-
pression by maintaining an unmethylated H3-K4 status
on a specific set of regulated promoters (Shi et al., 2004,
2005). Interestingly, the demethylase activity of LSD1
has been shown to be modulated by other proteins,
including CoREST and BHC80 (Shi et al., 2005; Lee
et al., 2005), and by other histone marks displayed around
the substrate (Forneris et al., 2005, 2006). Further-
more, LSD1 has been implicated in H3-K9 demethylation506 Cell 128, 505–518, February 9, 2007 ª2007 Elsevier Inc.that is associated with PSA gene activation in an AR-
dependent manner (Metzger et al., 2005) and has been
described as a component of the MLL1 coactivator com-
plex (Nakamura et al., 2002). More recently, additional de-
methylase enzymes have been described and include
JHDM1, which specifically demethylates dimethyl histone
H3 at lysine 36 (H3-K36; Tsukada et al., 2006), JMJD1A/
JHDM2A, which demethylates mono- and dimethyl H3-
K9 (Yamane et al., 2006), and JMJD2A, which demethy-
lates trimethyl H3-K9/K36 (Whetstine et al., 2006). These
enzymes belong to a large family of proteins that contain
a conserved JmjC domain, which has been shown to be
critical for demethylation (Trewick et al., 2005; Tsukada
et al., 2006). Together, these recent discoveries suggest
an important but still mostly unknown role exerted by de-
methylation events in regulated gene transcription.
Here we report an unexpectedly widespread recruit-
ment of the histone demethylase LSD1 to active pro-
moters, including most ERa gene targets in MCF7 cells,
and we find that LSD1 is needed for activation and is re-
quired to oppose the functions of three HMTs: RIZ1,
ESET, and Eu-HMTase1. For gene transcription, these
HMTs exert an inhibitory gatekeeper function, which is re-
quired to prevent recruitment of unliganded nuclear re-
ceptors and constitutive activation. Intriguingly, a similar
molecular strategy is also employed for ERa gene targets
that do not recruit LSD1 but utilize distinct combinations
of HMTs and HDMs to provide promoter specificity to
this HMT/HDM code. A similar code appears to exist
also for a number of other signal-dependent transcription
programs. In summary, we propose that a gatekeeper
strategy imposed by a selective use of HMTs and HDMs
is widely exploited in mammalian biology to determine
the appropriate physiological amplitude of regulated
gene transcription as orchestrated by nuclear receptors
and other classes of DNA-binding transcription factors.
RESULTS
A Broad Genome-Wide LSD1 Promoter-Binding
Program Detected by ChIP-DSL
Based on our interest in the role of corepressor complexes
in gene transcription regulation, we applied a new ge-
nome-wide chromatin immunoprecipitation (ChIP) assay
based on DSL (DNA selection and ligation; details in Sup-
plemental Experimental Procedures and in Kwon et al.,
2007) to several CoREST corepressor complex compo-
nents, including the specific histone lysine demethylase
LSD1. Recruitment of LSD1 in MCF7 cells that had been
treated with 17 b-estradiol (E2) was determined by the
ChIP-DSL method using a specific a-LSD1 antibody (Fig-
ure S1) and an array containing 20,045 human-proximal
promoters (Hu20K; Figure 1A). Statistical significance for
promoter enrichmentwas based on the analysis of a geno-
mic tiling component included on the array (Figure 1A, yel-
low dots). Based on data obtained from three independent
biological replicates, we unexpectedly detected a total of
4212 LSD1-enriched (LSD1+) promoters in these cells
Figure 1. Genome-Wide Promoter Analysis Reveals the Association of LSD1 with a Broad Gene Activation Program
(A) Scatter plot of LSD1 recruitment to human gene promoters is shown. E2-inducedMCF7 cells were profiled on the Hu20K array by ChIP-DSL. Three
biological replicateswere used to derive enriched promoters at p < 0.0001 (red), shown in comparison with intergenic genomic sequences as negative
controls (yellow). Weighted average is visualized on a single experiment scatter plot.
(B) Scatter plot of a nonrelevant antibody profiled on the Hu20K array by ChIP-DSL is shown. Two biological replicates were used.
(C) Number and percentage of LSD1+ promoters on the Hu20K array at different statistical cutoffs are shown.
(D) ChIP/qPCR analysis of 17 LSD1+ and 8 LSD1 randomly selected promoters in E2-stimulated MCF7 cells is shown. The data are the average of
three replicates, and error bars represent ± standard error mean.
(E) Venn diagram of LSD1+ and Pol II+ promoters obtained by ChIP-DSL is shown. Only promoters with reliable signal intensities in both profiling ex-
periments were included in the comparison.
(F) ChIP/qPCR analysis of Pol II recruitment on selected LSD1+ and LSD1 promoters in E2-stimulatedMCF7 cells is shown. The data are the average
of three replicates, and error bars represent ± standard error mean.
(G) Correlation of gene expression (light blue) with promoter occupancy (dark blue) is shown and includes histonemodificationmarks (DiMeH3K4 and
AcH3K9) as well as Pol II and LSD1, which were profiled in E2-induced MCF7 cells. Only genes included in both promoter- and expression-profiling
arrays and reliably scored in all measurements were used to construct the binary map by unsupervised hierarchical clustering analysis.
(H) LSD1+ genes classified by mRNA expression status are shown.(22% of the Hu20K array that showed reliable signals)
even at a highly stringent selection criteria (p < 0.0001),
while 118 promoters were detected with an irrelevant an-
tibody using the same criteria (Figures 1A and 1B, red
dots). The number of LSD1+ promoters would increase
to 5174 promoters (27% of the array) or 6570 promoters(34% of the array) if the selection criteria were relaxed to
a more conventional stringency (p < 0.001 and p < 0.01,
respectively; Figure 1C). These results were validated by
conventional ChIP assay and quantitative PCR (qPCR)
analysis on randomly selected LSD1+ promoters at
p < 0.0001 (Figure 1D).Cell 128, 505–518, February 9, 2007 ª2007 Elsevier Inc. 507
Consistent with the predictive value of this assay, virtu-
ally all known LSD1-target promoters represented on the
Hu20K array were detected as LSD1+, including the re-
pressed SYN1 (Hakimi et al., 2002) and SCN3A (Shi
et al., 2004) promoters (Figure S2). The multiple experi-
mentally confirmed or computationally predicted NRSF/
REST-target genes found as LSD1+ (e.g., CX36, DNM1,
PAX4, and SYT2; Andres et al., 1999; Ballas et al., 2001;
Hakimi et al., 2002; Lunyak et al., 2002; Figure S3A) and
the enrichment of NRSF/REST-predicted sites observed
in LSD1+ neuronal-specific genes (Figure S3B) are consis-
tent with the model that, as a component of the CoREST
complex, LSD1 is functionally important in negatively reg-
ulating neuronal NRSF/REST-dependent genes in non-
neuronal cells (Andres et al., 1999; Ballas et al., 2001,
2005; Humphrey et al., 2001; You et al., 2001; Hakimi
et al., 2002; Lunyak et al., 2002; Shi et al., 2003, 2004;
Bruce et al., 2004).
Broad LSD1 Promoter Binding Is Primarily
Associated with Gene Activation Events
In addition to the role of LSD1 in transcriptional repression
(Figures S2 and S3), 84% of LSD1+ promoters were Pol
II+ and, quite unexpectedly, a full 42% of all Pol II+ pro-
moters in MCF7 cells were LSD1+ (Figure 1E). These re-
sults were confirmed by conventional ChIP/qPCR assay
(Figure 1F). Similarly, examination of histone marks was
consistent with the preponderance of activated, rather
than repressed, LSD1+ promoters. Indeed, dimethylation
of histone H3 lysine 4 (diMeH3K4), a substrate for LSD1
demethylation activity associated with LSD1 repressive
functions (Shi et al., 2004, 2005; Lee et al., 2005), and
acetylation of histone H3 lysine 9 (acH3K9), another well-
established mark that correlates with gene activation,
exhibitedaconsiderableoverlappingpatternwith thepres-
enceof LSD1ongenepromoters (Figure 1G). Theseobser-
vations were corroborated by clustering ChIP-DSL and
mRNA-profiling data sets obtained inMCF7 cells, thus ob-
serving74%LSD1+ genes as expressed (Figures 1G and
1H). Taken together, our data suggest that the percentage
of activated transcription units modulated by LSD1
(74%–84%) is substantially larger than the percentage
of activated transcription units (16%–26%) included in
the LSD1-repressed program (Figures 1E and 1H).
Recently, we identified 578 promoters that exhibit ERa
binding in MCF7 cells (Kwon et al., 2007). Surprisingly,
58% of ERa-enriched (ERa+) promoters also exhibited
LSD1 recruitment (319 ERa+/LSD1+ promoters); these
represented 9% of all LSD1+ promoters (Figure 2A). In
addition, genomic tiling analysis using ChIP-DSL assay
of two well-established ERa-regulated target genes,
TFF1/pS2 and GREB1, revealed LSD1- and ERa-core-
cruitment on presumed ERa-binding enhancer sites that
were located 10 Kb upstream of TFF1/pS2 and 40
Kb upstream of GREB1 gene start sites (Figure 2B). This
ChIP-DSL analysis also showed that an ERa coactivator,
CBP, and an ‘‘activation’’ histone mark, AcH3K9, ex-
hibited similar profiles (Figure 2B). For all factors tested,508 Cell 128, 505–518, February 9, 2007 ª2007 Elsevier Inc.including LSD1, the occupancy on both distal and proxi-
mal promoter cognate DNA sites was shown to be stimu-
lated by E2 treatment as determined by ChIP/qPCR
(Figure 2C). In addition, LSD1 recruitment on promoters
of other LSD1+/ERa+-target genes was also stimulated
by E2 (Figure 2D). In agreement with these data, coimmu-
noprecipitation experiments in whole MCF7 cell extract
using a-LSD1 antibody demonstrated a specific E2-de-
pendent interaction of LSD1 with endogenous ERa and
CBP, and vice versa (Figures 2E and 2F).
Ligand-Dependent Induction of ERa-Regulated
Targets Requires Functionally Active LSD1
We next assessed the functional requirement of LSD1 in
gene activation of ERa-regulated genes and found that
E2-dependent induction of LSD1
+/ERa+-target genes
(pS2, GREB1, CTSD, andMYC) was essentially abolished
in MCF7 cells in which LSD1was knocked down by siRNA
(Figures 3A, 3B, and S4A). By contrast, analysis on an
LSD1/ERa+-target gene,WISP2, revealed that depletion
of LSD1 had no effect on its ligand-dependent activation
(Figure 3C).
To test the role of the amine oxidase activity of LSD1 on
regulation of LSD1+/ER+ targets, a rescue experiment was
performed by single-cell nuclear microinjection assay; in
this experiment, wild-type human LSD1 (wt hLSD1) or
a predicted amine oxidase-inactive human form (mut
hLSD1) was injected in Rat-1 cells that were simulta-
neously depleted of the endogenous rat LSD1 by microin-
jection of rLSD1siRNA. While WT hLSD1 rescued the E2-
induced activation of a pS2 promoter LacZ reporter, the
mut hLSD1was unable to rescue the reporter gene activity
(Figure 3D). Similarly, transient transfection of wt hLSD1
but not mut hLSD1 caused an E2-dependent increase in
the activity of an ERE-Luc reporter (Figure S5). Therefore,
the amine oxidase activity, which was proven to be re-
quired for mediating LSD1-dependent H3-K4 and H3-K9
demethylation (Shi et al., 2004; Metzger et al., 2005), is
also necessary for LSD1/ERa-dependent gene activation.
We next addressed any H3-K4 and H3-K9 demethyla-
tion event that might occur upon E2 stimulation of LSD1/
ERa-dependent gene targets. While ERa binding and
acH3K9 were increased as a result of E2 treatment (Fig-
ures 3E and 3F), we observed, by quantitative ChIP/
qPCR on promoter and distal pS2 and GREB1 ERa-target
sites, a consistent decrease in both diMeH3K4 and
diMeH3K9 (Figures 3G and 3H). Importantly, no simulta-
neous increases in trimethylation status were observed
on the same sites (Figures 3I and 3J). In concert, these
findings suggest that H3-K9 and H3-K4 methylation
dynamics are key components of the gene activation
program mediated by LSD1.
Mechanisms Underlying the LSD1-Dependent
Gene Activation
To understand the mechanism underlying the functional
requirement for LSD1 in E2-dependent induction, we
examined the impact of removing various H3-K9 and
Figure 2. LSD1 Associates with Most ERa-Promoter Targets in MCF7 Cells
(A) Venn diagram of LSD1+ and ERa+ promoters as obtained by ChIP-DSL is shown. Only promoters with reliable signal intensities in both profiling
experiments were included in the comparison.
(B) ChIP-DSL tiling array analysis onGREB1 (left panel) and TFF1/pS2 (right panel) loci of ERa, CBP, LSD1, AcH3K9, and Pol II occupancy in E2-stim-
ulated MCF7 cells is shown. Binding profiles represent ChIP versus input DNA intensity ratios (right). The most enriched ERa-binding sites (proximal
and distal) are indicated by arrows. DSL probe location and RefSeq gene annotation are indicated in the bottom.
(C) ChIP/qPCR recruitment analysis of ERa, CBP, and LSD1 on proximal and distal ERa-binding sites upon E2 treatment in MCF7 cells is shown. The
data are the average of three replicates, and error bars represent ± standard error mean.
(D) ChIP/qPCR analysis of LSD1 and ERa recruitment on additional LSD1+/ERa+ promoters detected by ChIP-DSL assay upon E2 treatment in MCF7
cells is shown. The data are the average of three replicates, and error bars represent ± standard error mean.
(E) shows coimmunoprecipitation analysis of ERa andCBPby anti-LSD1 antibody in cell extracts obtained fromE2-stimulatedMCF7 cells. 5% input is
shown.
(F) Coimmunoprecipitation analysis of LSD1 by anti-ERa antibody in cell extracts obtained from unstimulated and E2-stimulatedMCF7 cells is shown.H3-K4 HMTs (Martin and Zhang, 2005) by siRNA on E2-
dependent induction. Depletion of known H3-K4 HMTs,
including MLL1, had little effect on basal pS2 activity(data not shown). However, depletion of several specific
H3-K9 HMTs, including RIZ1, ESET, and Eu-HMTase1,
but not G9a or Suv39h1/h2, derepressed the pS2Cell 128, 505–518, February 9, 2007 ª2007 Elsevier Inc. 509
Figure 3. LSD1 Regulates E2-Dependent Gene Transcription While Both H3-K4 and H3-K9 Demethylation Events Are Observed
(A) Real-time qPCR (RT-qPCR) analysis is shown to document efficiency of LSD1 siRNA to diminish endogenous LSD1.
(B) RT-qPCR analysis of several endogenous LSD1+/ERa+-target genes upon LSD1 siRNA transfection is shown.
(C) RT-qPCR analysis of an endogenous LSD1/ERa+-target gene upon LSD1 depletion by siRNA is shown. In (A)–(C) LSD1 siRNA was delivered by
transient transfection in MCF7 cells, and b-actin mRNA expression levels as well as cell transfection efficiency were used for normalization.
(D) Functional rescue analysis of the wild-type (wt) and the amine oxidase mutant (mut) human LSD1 form (hLSD1) in Rat-1 cells is shown. Endog-
enous rat LSD1 (rLSD1) expression was depleted by specific rat LSD1 siRNA, and ectopic wt hLSD1 and mut hLSD1 overexpression was accom-
plished by expression plasmids. Reporter plasmid and LSD1 siRNA were delivered by single-cell nuclear microinjection in Rat-1 cells.
(E–J) Panels show ChIP/qPCR occupancy analysis of ERa (E), acH3-K9 (F), diMeH3-K4 (G), diMeH3-K9 (H), TriMeH3-K4 (I), and TriMeH3-K9 (J) on
ERa-binding sites in vehicle- or E2-treated MCF7 cells. ERa proximal or distal binding sites on pS2 and GREB1 genomic loci were examined; HIG2
promoter was included as control. The data in (A)–(J) are the average of three replicates, and error bars represent ± standard error mean.promoter; this resulted in full activation in the absence of
ligand (Figure 4A), while no significant effects were ob-
served after depletion of these three enzymes in the pres-
ence of ligand (Figure 4B). Thus, in the absence of these
specific H3-K9 HMTs, regulated activation of pS2 gene
now became LSD1 independent (Figure 4C). Consistent
with these observations, mRNA levels of endogenous
pS2 and GREB1 genes were upregulated upon siRNA-
mediated RIZ1/ESET depletion even in the absence of li-
gand without any effect on response observed in the pres-
ence of ligand (Figures 4D, 4E, and S4B). To demonstrate
the specificity in knockdown experiments, we observed at510 Cell 128, 505–518, February 9, 2007 ª2007 Elsevier Inc.least a partial (70%) functional rescue of the repressive
ESET activity in HeLa cells in which the endogenous
human ESET (hESET) was depleted by specific hESET
siRNA, and the mouse form of this HMT (mESET) was
overexpressed (Figure 4F). In addition, the binding of
ESET and RIZ1 on pS2 and GREB1 promoters was found
to be decreased upon E2 stimulation as quantified by
ChIP/qPCR (Figure 4G). Together, these data suggest
that a critical function of LSD1 is to reverse the inhibitory
effect of several H3-K9 HMTs: RIZ1, ESET, and Eu-
HMTase1, the presence of which dictates LSD1 depen-
dency for gene activation.
Figure 4. Specific H3-K9 HMTs Function as Inhibitory Gatekeepers and Dictate LSD1 Dependency for ERa-Regulated Gene
Activation
(A and B) Effect of different siRNAs to specific H3-K9 HMTs on pS2 promoter-LacZ reporter activity was analyzed by single-cell microinjection assay
in the absence (A) and presence (B) of ligand (E2).
(C) Functional LSD1 dependency of pS2 promoter-LacZ reporter activity was tested after depletion of specific H3-K9 HMTs.
(D) RT-qPCR analysis was performed to document efficiency of H3-K9 HMTs siRNAs to diminish endogenous RIZ1 and ESET.
(E) RT-qPCR analysis of endogenous ERa-target genes upon specific H3-K9 HMTs siRNA transfection is shown.
(F) Functional rescue analysis of a mouse ESET form in HeLa cells is shown. Endogenous human ESET (hESET) expression was abolished by specific
mouse ESET siRNA, and ectopic mouse ESET (mESET) overexpression was accomplished by expression plasmid.
(G) Panel shows ChIP/qPCR recruitment analysis of RIZ1 and ESET on endogenous ERa-target promoters upon E2 stimulation in MCF7 cells.
(H) Functional analysis of CaMKIIg in absence of ligand (E2) on a pS2 promoter-LacZ reporter gene is shown. For experiments (A)–(C), (F), and (H)
reporter plasmid and siRNAs were delivered by single-cell nuclear microinjection in MCF7 and HeLa (in F) cells. In (D) and (E) siRNAs were delivered
by transient transfection in MCF7 cells, and b-actin expression levels and cell transfection efficiency were used for normalization. The data in (A)–(H)
are the average of three replicates, and error bars represent ± standard error mean.The requirement for more than one H3-K9 HMT im-
plies that, at least for some genes, these enzymes are
not fully functionally redundant; this has also been re-cently shown for similar nonredundant HDM activities
(Yamane et al., 2006). Interestingly, at least one of the
specific H3-K9 HMTs, RIZ1, has been proposed to actCell 128, 505–518, February 9, 2007 ª2007 Elsevier Inc. 511
Figure 5. H3-K9 HMTs Impose Ligand Dependency to the E2-Dependent Signaling Pathway
(A) ERa dependency of the pS2 promoter-LacZ reporter activity is analyzed in absence of specific H3-K9 HMTs.
(B) RT-qPCR analysis was performed to document efficiency of ERa, RIZ1, and ESET siRNAs to diminish endogenous ERa, RIZ1, and
ESET.
(C) RT-qPCR analysis of endogenous ERa-target genes after removing H3-K9 HMTs and ERa by siRNA is shown.
(D) ChIP/qPCR recruitment analysis of ERa in cells transfected with specific H3-K9 HMTs siRNAs in absence or presence of ligand (E2) is
shown.
(E) Analysis of pS2 promoter-LacZ reporter activity upon removing the ERa-associated coactivators CBP, pCIP, and SRC1 in cells depleted of the
H3-K9 HMT RIZ1. For experiments (A) and (E), reporter plasmid and siRNAs were delivered by single-cell nuclear microinjection in MCF7 cells. In
(B)–(D), siRNAs were delivered by transient transfection in MCF7 cells, and b-actin mRNA expression levels and cell transfection efficiency were
used for normalization. The data in (A)–(E) are the average of three replicates, and error bars represent ± standard error mean.as a tumor-suppressor gene that is silenced inmany highly
metastatic breast cancer cell lines (He et al., 1998; Du
et al., 2001), and RIZ1 siRNA-depleted MCF7 cells
showed increased levels of cell proliferation (Carling
et al., 2004; Gazzerro et al., 2006). Indeed, cell prolifera-
tion and cell-cycle control were the top two ER+ gene
ontology-enriched terms that were revealed by ChIP-
DSL analysis of ERa in MCF7 cells (Kwon et al., 2007),
suggesting a global upregulation of ER+ gene targets in
the absence of RIZ1.
Because of the connection between specific protein ki-
nases, including CaMKs, and the actions of repressive
HMTs (Ishitani et al., 2003; Zhang, et al., 2002; Kurahashi
et al., 2005), we tested the possibility that CaMKII
might modulate H3-K9 HMTs and, hence, LSD1- and E2-
dependent gene activation events. Interestingly, specific
CAMKIIg siRNA resulted in full, LSD1-independent activa-
tion of the pS2-reporter gene (Figure 4H), which strongly
suggests a link between specific signaling pathways
and an HMT-dependent imposition of inhibitory histone
marks.512 Cell 128, 505–518, February 9, 2007 ª2007 Elsevier Inc.A Balance between Histone Lysine Methylation
and Demethylation Events Determines Ligand
Dependency of ERa Targets
The observation of ‘‘ligand-independent’’ gene activation
in the absence of specific H3-K9 HMTs raised the ques-
tion of whether ERa is still critically required for activation
in the absence of these enzymes and LSD1. To investigate
this issue, siRNA depletion of ERa, along with RIZ1 or
ESET, was performed in MCF7 cells and revealed that,
in the absence of ERa, pS2 promoter activation was abol-
ished (Figure 5A). These results, which are fully in concert
with the observation that unliganded ERa can still bind to
and even recycle at low levels on the pS2 promoter (Metiv-
ier et al., 2004; Perissi et al., 2004), were confirmed on
endogenous ERa-target genes (Figures 5B and 5C).
ChIP analysis of RIZ1/ESET siRNA-depleted cells
showed an increased recruitment of ERa, in absence of
E2, to a level equivalent to that observed with E2, thus sup-
porting the hypothesis that one critical function of H3-K9
HMTs is to inhibit recruitment of unliganded ERa to its tar-
get genes (Figure 5D). Furthermore, well-established ERa
coactivators, including CBP and SRC1-p/CIP, were re-
quired for this LSD1- and ligand-independent activation
(Figure 5E). In contrast, the depletion of these same
HMTs caused neither activation (data not shown) nor in-
creased ERa binding on the LSD1-independent ERa tar-
getWISP2 promoter (Figure 5D), suggesting a role of other
combinations of HMTs/HDMs in ERa regulation of LSD1-
independent genes (see below).
Based on the broad recruitment of LSD1 on proximal
promoters (Figure 1C), we determined the LSD1 depen-
dency of several additional regulated gene activation pro-
grams. LSD1 siRNA microinjection experiments revealed
a similar role of LSD1 in activation of AR, as previously
shown (Metzger et al., 2005; Yamane et al., 2006). In addi-
tion, these experiments revealed a role of LSD1 in activa-
tion of NFkB-, AP-1-, and bRAR-regulated promoters,
but not in the case of CREB-regulated gene targets
(Figure S6). These data suggest that LSD1 is selectively in-
volved in induction of a subset of regulated transcription
units but is not universally required for gene activation.
Analogous to ERa, RIZ1 and ESET appeared to exert
a similar role in AR-dependent activation of the PSA
gene (Figures 6A and S7A) as suggested by the partial de-
repression of PSA expression levels and the LSD1-inde-
pendent activation of the same gene, which were again
produced in the absence of specific H3-K9 HMTs. Simi-
larly, depletion of RIZ1/ESET resulted in activation of
NFkB-target genes in absence of signal, and this activa-
tion also exhibited dependency on the presence of
NFkB factors (Figures S7B–S7D). Based on these data,
we propose that a major biological role for the opposing
actions of RIZ1/ESET/Eu-HMTase1 and LSD1 is to confer
high amplitude of ligand response or signal dependency of
gene activation on cohorts of regulated transcription units.
Promoter-Specific HMT/HDM ‘‘Code’’ for Regulated
Transcription Units
Because pS2 and GREB1 require LSD1 for activation,
while WISP2 does not, a key question is whether entirely
distinct molecular strategies are used for LSD1+- and
LSD1-regulated transcription units or whether distinct
HMTs and HDMs are required to mediate a similar regula-
tory mechanism. As a new AR-specific H3-K9 HDM,
JMJD1A/JHDM2A, has recently been reported (Yamane
et al., 2006), we examined whether this enzyme exerts
a similar role on LSD1+/ERa-regulated targets and, alter-
natively, whether this factor might substitute for LSD1 on
LSD1/ERa+ gene targets. The specific depletion of
JMJD1A by siRNA in LNCaP cells confirmed that this fac-
tor was required for ligand-dependent activation of AR-
target genes (Figures 6B and 6C), as previously shown
(Yamane et al., 2006). Because LSD1 is also required
(Figure 6A; Metzger et al., 2005), these AR-target genes
demonstrate that at least two HDMs are required for full
activation (Yamane et al., 2006). In contrast, ERa-depen-
dent activation of pS2 and GREB1 gene targets depends
on LSD1 but not on JMJD1Awhen similar experiments are
performed in MCF7 cells (Figures 6D–6F). Interestingly,however, an unexpected activation of the pS2 promoter
was observed in the absence of ligand (Figures 6D–6F).
Based on these findings, we next explored whether an
LSD1/ERa+ gene target, WISP2, might use JMJD1A
and HMTs other than ESET/RIZ1/EuHMTase to mediate
a strategy of regulation similar to that utilized by LSD1
and these enzymes for pS2. Interestingly, while LSD1
siRNA did not inhibit ligand-dependent activation
(Figure 3C), JMJD1A siRNA blocked E2-dependent stimu-
lation ofWISP2 (Figure 6G), andG9A but notSUV39H1/H2
siRNAs permitted a partial activation (50%) in the
absence of ligand (Figure 6H). Together, these results pro-
vide compelling evidence for a widely used, promoter-
specific code in regulated transcription, with different
cohorts of targets requiring distinct combinations of HMTs
and HDMs. It is interesting to note that for some genes,
loss of HMTs alone causes a level of activation similar to
that observed in response to ligand, while for others,
only a partial activation, with further enhancement when
ligand is present, is observed.
DISCUSSION
Here we report an unexpected mechanism that proves to
be physiologically utilized to prevent constitutive gene ac-
tivation by unliganded nuclear receptors and other clas-
ses of signal-dependent DNA-binding transcription fac-
tors. We have identified three specific H3-K9 HMTs that
potentially act as gatekeepers for the 58% of ERa
gene targets that are LSD1+ and that maintain a repressive
status that precludes unliganded nuclear receptors, such
as ERa, from effective binding and from functioning as
ligand-independent, constitutive activators (Figure 6I). In-
deed, transcriptional activation by unliganded nuclear
receptors has been reported on removal of corepressors
and on activation by specific signaling pathways (Culig
et al., 1994; Nazareth and Weigel, 1996; Zwijsen et al.,
1997; Rogatsky et al., 1999; Ueda et al., 2002; Ogawa
et al., 2004; Kim et al., 2005).
Our data support the model that inhibitory HMTs pre-
vent unregulated activation of these targets, at least in
part, by blocking the binding of unliganded ERa to its cog-
nate DNA sites. The binding of liganded ERa on these reg-
ulated promoters thereafter permits the recruitment of the
LSD1 enzymatic activity that is required to dismiss the
inhibitory marks and, potentially, methyl marks of other
nonhistone substrates (I.G.-B. and M.G.R., unpublished
results), thus permitting other ERa-recruited coactivators
to initiate the regulated transcriptional response
(Figure 6I). Thus, exchange of inhibitory histone lysine
methyl marks based on the actions of specific, and not
fully redundant, H3-K9 HMTs as well as the actions of crit-
ical HDMs are required to permit a ligand-dependent
response. Therefore, while REST/CoREST-dependent
genes clearly employ LSD1 in repression for at least a co-
hort of the REST-dependent program (Shi et al., 2004; Fig-
ures S2 and S3), our results have also revealed that LSD1,
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Figure 6. A Promoter-Specific HMT/HDM ‘‘Code’’ for Regulated Transcription Units
(A) RT-qPCR analysis of an endogenous LSD1+/AR+ gene target upon RIZ1/ESET and/or LSD1 depletion by siRNA in LNCaP cells is shown.
(B) RT-qPCR analysis to document the efficiency of JMJD1A siRNA to diminish endogenous JMJD1A in LNCaP cells is shown.
(C) RT-qPCR analysis of endogenous AR-target genes upon JMJD1A depletion by siRNA is shown.
(D) Functional analysis of the pS2 promoter-LacZ reporter gene activity after removing JMJD1A by microinjection of siRNA in MCF7 cells is shown.
(E) RT-qPCR analysis was performed to document efficiency of JMJD1A siRNA to diminish endogenous JMJD1A in MCF7 cells.
(F) RT-qPCR gene expression analysis of endogenous LSD1+/ERa+-target genes upon JMJD1A depletion by siRNA is shown.
(G) RT-qPCR analysis of an endogenous LSD1/ERa+-target gene upon JMJD1A depletion by siRNA is shown.
(H) RT-qPCR gene expression analysis of an endogenous LSD1/ERa+-target gene upon G9a or Suv39h1/h2 depletion by siRNA is shown.
(I) Model of H3-K9 HMT requirement to inhibit constitutive ERa activation by blocking binding of the unliganded nuclear receptor to its cognate DNA
sites is shown; HDMs, as LSD1, are required to demethylate H3-K9 HMTs substrates to permit activation by liganded ERa (see text for details).
(J) Gene-specific use of HMT/HDMs to define regulated gene activation programs (see text for details) is shown. In all these experiments, siRNA was
delivered by transient transfection in LNCaP (A)–(C) or MCF7 cells (D)–(H), and b-actin expression levels and cell transfection efficiency were used for
normalization. The data in (A)–(H) are the average of three replicates ± standard error of the mean.514 Cell 128, 505–518, February 9, 2007 ª2007 Elsevier Inc.
et al., 2002; Guenther et al., 2005), is required for a surpris-
ingly broad range of regulated gene activation events.
We further suggest that the HMT/HDM cycle provides
a licensing mechanism for signal-dependent gene activa-
tion of other classes of regulated transcription factors that
are required for normal development and homeostasis.
Gene-Specific Use of HMT/HDMs to Define
Regulated Gene Activation Programs
Because LSD1 is recruited only to a subset of ERa-target
genes, we were keen to initially examine the possibility
that a similar inhibitory histone code and degree of HMT/
HDM usagemight act on genes even when LSD1 is not re-
cruited to the promoter. Recently it has been reported that
the mono- and dimethyl H3-K9 HDM, JMJD1A/JHDM2A,
contributes with LSD1 to the hormone-induced H3-K9 de-
methylation of thePSA promoter/enhancer (Metzger et al.,
2005; Yamane et al., 2006), and that an additional H3-K9
demethylase, JMJD2A, displays specific trimethyl H3-
K9/K36 activity (Whetstine et al., 2006). Therefore, analo-
gous to histone deacetylase enzymes (HDACs), several
H3-K9 HMTs and HDMs could be present in the same
multiprotein complex (McKinsey et al., 2001; Yang and
Seto, 2003; Ogawa et al., 2002; Shi et al., 2003) and might
act to regulate gene expression in a nonredundant fashion
involving additional, distinct substrates.
Here, we have shown that distinct HMTs and HDMs are
utilized in a promoter-specific fashion (Figure 6J). For ex-
ample, the LSD1/ERa+ WISP2-target gene requires
JMJD1A for ligand-dependent activation, in which G9a
is selectively required to prevent ligand-independent con-
stitutive activation. However, LSD1 but not JMJD1A is
necessary for E2-dependent activation of the ERa
+-target
genes pS2 andGREB1, while both LSD1 and JMJD1A are
required for DHT activation of the KLK2 and PSA genes. It
is therefore tempting to speculate that there will be multi-
ple cohorts of target genes for each nuclear receptor that
depend on a similar strategy to prevent constitutive acti-
vation, but each will utilize unique combinations of HMTs
and HDMs to license ligand-regulated expression.
While we would predict the existence of additional sub-
strates other than H3-K9, for H3-K9 HMTs, andH3-K4/K9,
for LSD1, we propose that ultimately the inhibitory gate-
keeper strategy that is imposed by different HMTs blocks
ligand-independent receptor binding and constitutive
gene activation. This gatekeeper function is biologically
overcome on binding of liganded receptors and specific
H3-K9 HDMs. The requirement for three different HMTs,
RIZ1/PRDM5 (Steele-Perkins et al., 2001), ESET/SETDB1
(Yang et al., 2002; Schultz et al., 2002; Wang et al., 2003),
and Eu-HMTase1/GLP (Ogawa et al., 2002), for at least
some ERa-target genes, suggests that these SET-domain
enzymes are not fully functionally redundant (Schultz
et al., 2002; Wang et al., 2003), as seems to similarly occur
for at least two HDMs, LSD1 and JMJD1A/JHDM2A, for
the regulation of some AR-target genes (Metzger et al.,
2005; Yamane et al., 2006). As this represents an analo-
gous strategy involving different HMTs and HDMs, thelink between histone marks in preventing constitutive ac-
tivation of physiologically regulated genes appears to be
a general strategy.
H3-K4 and H3-K9 Demethylation in E2-Dependent
Gene Activation
At least two different dimethylated lysines have been pro-
posed to be demethylated by LSD1: the well-documented
H3-K4 (Shi et al., 2004, 2005; Lee et al., 2005) and H3-K9
(Metzger et al., 2005). LSD1 was found by ChIP-DSL to be
mainly associated with the presence of dimethyl H3-K4 on
the genome (Figure 1G). Indeed, although a certain degree
of H3-K4 demethylase activity was observed upon activa-
tion of ERa targets, high remaining levels of this mark were
still observed after LSD1 binding and activation, which
would agree with the high overlapping pattern detected
(Figure 3G). In contrast, it is proposed that this mark is fully
removed by LSD1 on targets that are repressed by NRSF,
which is supposed to confer gene repression (Shi et al.,
2004). Thus, LSD1 might switch activity depending on the
promoter, which is consistent with the ability of CoREST
and BHC80 to modify LSD1 enzymatic activity in vitro
(Shi et al., 2005; Lee et al., 2005), therefore displaying
H3-K4 demethylase on NRSF targets and H3-K9 deme-
thylase on AR, ERa, and other factors’ target promoters.
Also, one of the two reported LSD1 activities might be se-
lectively inactivated by the surrounding histone marks
present around the promoter. Indeed, specific histone
marks, such as AcH3-K9, inhibit H3-K4 demethylation
in vitro (Forneris et al., 2005, 2006). Of course, both activ-
ities could be also equally utilized on all promoters, with
the final levels of histone methylation being indeed
determined by the predemethylation levels.
The regulatory roles of these two histone methylation
marks on gene activation of euchromatic promoters
have been the subject of intense investigation during the
past few years. For example, methylation of H3-K9 has
been described to decrease on a subset of inflammatory
genes upon LPS stimulation (Saccani and Natoli, 2002).
Similarly, an inverse relationship between H3-K9 methyla-
tion and NFkB p65 binding on the IL-1b promoter has
been observed upon LPS stimulation in THP-1 cells
(Chan et al., 2005). Dimethylation of H3-K9 but also H3-
K4 has been described to decrease when T3R shifted
from an unliganded state to a liganded, active state (Li
et al., 2002), and a dramatic decrease in H3-K4 occurred
on a tandem array of the mouse mammary tumor virus
(MMTV) promoter upon induction by glucocorticoids (Ma
et al., 2001). Finally, a decline in both dimethyl H3-K4
(Kim et al., 2003) and dimethyl H3-K9 (Metzger et al.,
2005) has been reported on the PSA promoter upon
DHT induction, and here we show that both histone marks
are simultaneously decreased upon ERa/E2-dependent
activation of several promoters. Thus, dynamic changes
of H3-K4 and H3-K9 methylation seem to occur in a diver-
sity of programs.
In conclusion, an important aspect of the serial post-
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transcription factors, which constitute a component of the
hypothesized ‘‘histone code,’’ is to impose signal/ligand
dependency to regulated DNA-binding transcription fac-
tors by modulatory binding of unliganded receptors and
other classes of transcription factors, thereby preventing
constitutive activation of cohorts of target genes.
EXPERIMENTAL PROCEDURES
Materials and Reagents
Anti-LSD1 antibody was generated in guinea pigs against bacterially
expressed N0-terminal region (13–219 aa) of the human LSD1.
Anti-CoREST antibody was a generous gift from Dr. Gail Mandel.
Commercially available antibodies and siRNAs are documented in
Supplemental Data.
ChIP Assay
MCF7 breast cancer cells were hormone deprived for 4 days and then
treated for 1 hr with 100 nM 17b-estradiol (E2). ChIP assay was con-
ducted as previously described (Zhu et al., 2006). Further details and
list of primers used for PCR validation are available in Supplemental
Data.
ChIP-DSL Assay
Genome-wide promoter location analysis by ChIP-DSL on Hu20K and
HuTiling arrays was performed and analyzed as described in Supple-
mental Experimental Procedures and in Kwon et al., 2007. Biological
triplicates were performed in each case.
Single-Cell Nuclear Microinjection Assay
The small interfering RNAs (siRNAs) were delivered into cells by single-
cell microinjection assay as previously described (Kamei et al., 1996;
Heinzel et al., 1997). Details and siRNA information are available in
Supplemental Experimental Procedures.
Transient Transfection Assay
Transient transfection assay in MCF7 cells was performed using Lipo-
fectamin 2000, following manufacturer’s protocol (Invitrogen).
RNA Isolation, Real-Time PCR, and RNA Profiling Analysis
RNA was extracted by RNeasy Assay (Qiagen), and cDNA was ob-
tained by SuperScript First-Strand Synthesis System (Invitrogen) fol-
lowing both manufacturers’ protocols. RNA profiling was performed
as described by Kwon et al., 2007. Further details and list of primers
used for PCR amplification are available in Supplemental Experimental
Procedures.
Immunoprecipitation
Immunoprecipitation assay was conducted as previously described
(Bannister and Kouzarides., 1996). Details are available in Supplemen-
tal Experimental Procedures.
Real-Time qPCR
Semi-qPCR was carried out according to the Mx3000P Real-Time
PCR Systems manual and the Brilliant qPCR reagent kit (Stratagene).
Details are available in Supplemental Experimental Procedures.
Supplemental Data
Supplemental Data include seven figures, Supplemental Experimental
Procedures, and Supplemental References and can be found with this
article online at http://www.cell.com/cgi/content/full/128/3/505/DC1/.
ACKNOWLEDGMENTS
We thank colleagues in our laboratories, especially C.A. Nelson and
A. Krones for technical assistance. We also thank Dr. V. Perissi for crit-516 Cell 128, 505–518, February 9, 2007 ª2007 Elsevier Inc.ical reading of the manuscript and Dr. A. Almenar-Queralt for generous
help; Dr. A. Aggarwal for advice on prediction of essential enzymatic
LSD1 residues; Dr. G. Mandel for kindly providing CoREST antibodies;
A. Gonzalez (Santa Cruz Technologies) for advice on reagents; and
J. Hightower and M. Fisher for figure and manuscript preparation.
We especially acknowledge Ron Margolis and Phil Smith (NIDDK)
and Laura Mamounas (NINDS) for their critical support in permitting
development of this technology. M.G.R. is an investigator with Howard
Hughes Medical Institute. This work is supported by CA97134,
DK39949, and NS34934 NIH grants, Vitamin Cases Consumer Settle-
ment Fund, and Army Concept Award BC0464 to M.G.R.; DK063491
and CA52599 NIH grants to C.K.G.; and CA114184 and HG003119
NIH grants to X.-D.F.
Received: April 13, 2006
Revised: July 27, 2006
Accepted: December 4, 2006
Published: February 8, 2007
REFERENCES
Andres, M.E., Burger, C., Peral-Rubio, M.J., Battaglioli, E., Anderson,
M.E., Grimes, J., Dallman, J., Ballas, N., and Mandel, G. (1999).
CoREST: a functional corepressor required for regulation of neural-
specific gene expression. Proc. Natl. Acad. Sci. USA 96, 9873–9878.
Ballas, N., Battaglioli, E., Atouf, F., Andres, M.E., Chenoweth, J.,
Anderson, M.E., Burger, C., Moniwa, M., Davie, J.R., Bowers, W.J.,
et al. (2001). Regulation of neuronal traits by a novel transcriptional
complex. Neuron 31, 353–365.
Ballas, N., Grunseich, C., Lu, D.D., Speh, J.C., and Mandel, G. (2005).
REST and its corepressors mediate plasticity of neuronal gene chro-
matin throughout neurogenesis. Cell 121, 645–657.
Bannister, A.J., and Kouzarides, T. (1996). The CBP co-activator is
a histone acetyltransferase. Nature 384, 641–643.
Bruce, A.W., Donaldson, I.J., Wood, I.C., Yerbury, S.A., Sadowski,
M.I., Chapman, M., Gottgens, B., and Buckley, N.J. (2004). Genome-
wide analysis of repressor element 1 silencing transcription factor/
neuron-restrictive silencing factor (REST/NRSF) target genes. Proc.
Natl. Acad. Sci. USA 101, 10458–10463.
Carling, T., Kim, K.C., Yang, X.H., Gu, J., Zhang, X.K., and Huang, S.
(2004). A histone methyltransferase is required for maximal response
to female sex hormones. Mol. Cell. Biol. 24, 7032–7042.
Chan, C., Li, L., McCall, C.E., and Yoza, B.K. (2005). Endotoxin toler-
ance disrupts chromatin remodeling and NF-kappaB transactivation
at the IL-1beta promoter. J. Immunol. 175, 461–468.
Chen, J.D., and Evans, R.M. (1995). A transcriptional co-repressor that
interacts with nuclear hormone receptors. Nature 377, 454–457.
Culig, Z., Hobisch, A., Cronauer, M.V., Radmayr, C., Trapman, J.,
Hittmair, A., Bartsch, G., and Klocker, H. (1994). Androgen receptor
activation in prostatic tumor cell lines by insulin-like growth factor-I,
keratinocyte growth factor, and epidermal growth factor. Cancer
Res. 54, 5474–5478.
Dou, Y., Milne, T.A., Tackett, A.J., Smith, E.R., Fukuda, A., Wysocka,
J., Allis, C.D., Chait, B.T., Hess, J.L., and Roeder, R.G. (2005). Physical
association and coordinate function of the H3 K4 methyltransferase
MLL1 and the H4 K16 acetyltransferase MOF. Cell 121, 873–885.
Du, Y., Carling, T., Fang, W., Piao, Z., Sheu, J.C., and Huang, S. (2001).
Hypermethylation in human cancers of the RIZ1 tumor suppressor
gene, a member of a histone/protein methyltransferase superfamily.
Cancer Res. 61, 8094–8099.
Fischle, W., Wang, Y., and Allis, C.D. (2003). Binary switches andmod-
ification cassettes in histone biology and beyond. Nature 425, 475–
479.
Flanagan, J.F., Mi, L.Z., Chruszcz, M., Cymborowski, M., Clines, K.L.,
Kim, Y.,Minor,W., Rastinejad, F., and Khorasanizadeh, S. (2005). Dou-
ble chromodomains cooperate to recognize themethylated histone H3
tail. Nature 438, 1181–1185.
Forneris, F., Binda, C., Vanoni, M.A., Battaglioli, E., and Mattevi, A.
(2005). Human histone demethylase LSD1 reads the histone code. J.
Biol. Chem. 280, 41360–41365.
Forneris, F., Binda, C., Dall’Aglio, A., Fraaije, M.W., Battaglioli, E., and
Mattevi, A. (2006). A highly specific mechanism of histone H3–K4 rec-
ognition by histone demethylase LSD1. J Biol Chem. 46, 35289–
35295.
Gazzerro, P., Abbondanza, C., D’Arcangelo, A., Rossi, M., Medici, N.,
Moncharmont, B., and Puca, G.A. (2006). Modulation of RIZ gene ex-
pression is associated to estradiol control of MCF-7 breast cancer cell
proliferation. Exp. Cell Res. 312, 340–349.
Guenther, M.G., Jenner, R.G., Chevalier, B., Nakamura, T., Croce,
C.M., Canaani, E., and Young, R.A. (2005). Global and Hox-specific
roles for the MLL1 methyltransferase. Proc. Natl. Acad. Sci. USA
102, 8603–8608.
Hakimi, M.A., Bochar, D.A., Chenoweth, J., Lane, W.S., Mandel, G.,
and Shiekhattar, R. (2002). A core-BRAF35 complex containing his-
tone deacetylase mediates repression of neuronal-specific genes.
Proc. Natl. Acad. Sci. USA 99, 7420–7425.
Hakimi, M.A., Dong, Y., Lane, W.S., Speicher, D.W., and Shiekhattar,
R. (2003). A candidateX-linkedmental retardation gene is a component
of a new family of histone deacetylase-containing complexes. J. Biol.
Chem. 278, 7234–7239.
He, L., Yu, J.X., Liu, L., Buyse, I.M., Wang, M.S., Yang, Q.C., Nakaga-
wara, A., Brodeur, G.M., Shi, Y.E., and Huang, S. (1998). RIZ1, but not
the alternative RIZ2 product of the same gene, is underexpressed in
breast cancer, and forced RIZ1 expression causes G2-M cell cycle ar-
rest and/or apoptosis. Cancer Res. 58, 4238–4244.
Heinzel, T., Lavinsky, R.M., Mullen, T.M., Soderstrom, M., Laherty,
C.D., Torchia, J., Yang, W.M., Brard, G., Ngo, S.D., Davie, J.R., et al.
(1997). A complex containing N-CoR, mSin3 and histone deacetylase
mediates transcriptional repression. Nature 387, 43–48.
Horlein, A.J., Naar, A.M., Heinzel, T., Torchia, J., Gloss, B., Kurokawa,
R., Ryan, A., Kamei, Y., Soderstrom, M., Glass, C.K., et al. (1995).
Ligand-independent repression by the thyroid hormone receptor me-
diated by a nuclear receptor co-repressor. Nature 377, 397–404.
Humphrey, G.W., Wang, Y., Russanova, V.R., Hirai, T., Qin, J.,
Nakatani, Y., and Howard, B.H. (2001). Stable histone deacetylase
complexes distinguished by the presence of SANT domain proteins
CoREST/kiaa0071 and Mta-L1. J. Biol. Chem. 276, 6817–6824.
Ishitani, T., Kishida, S., Hyodo-Miura, J., Ueno, N., Yasuda, J., Water-
man, M., Shibuya, H., Moon, R.T., Ninomiya-Tsuji, J., and Matsumoto,
K. (2003). The TAK1-NLK mitogen-activated protein kinase cascade
functions in the Wnt-5a/Ca(2+) pathway to antagonize Wnt/beta-cate-
nin signaling. Mol. Cell. Biol. 23, 131–139.
Jenuwein, T., and Allis, C.D. (2001). Translating the histone code. Sci-
ence 293, 1074–1080.
Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin,
S.C., Heyman, R.A., Rose, D.W., Glass, C.K., and Rosenfeld, M.G.
(1996). A CBP integrator complex mediates transcriptional activation
and AP-1 inhibition by nuclear receptors. Cell 85, 403–414.
Kim, J., Jia, L., Tilley, W.D., and Coetzee, G.A. (2003). Dynamic meth-
ylation of histone H3 at lysine 4 in transcriptional regulation by the an-
drogen receptor. Nucleic Acids Res. 31, 6741–6747.
Kim, J., Jia, L., Stallcup, M.R., and Coetzee, G.A. (2005). The role of
protein kinase A and cAMP response element-binding protein in an-
drogen receptor-mediated transcription at the prostate-specific anti-
gen locus. J. Mol. Endocrinol. 34, 107–118.Kouzarides, T. (2002). Histone methylation in transcriptional control.
Curr. Opin. Genet. Dev. 12, 198–209.
Kurahashi, T., Nomura, T., Kanei-Ishii, C., Shinkai, Y., and Ishii, S.
(2005). The Wnt-NLK signaling pathway inhibits A-Myb activity by in-
hibiting the association with coactivator CBP and methylating histone
H3. Mol. Biol. Cell 16, 4705–4713.
Kwon, Y.-S., Garcia-Bassets, I., Hutt, K.R., Cheng, C.S., Jin, M., Liu,
D., Benner, C., Wang, D., Ye, Z., Bibikova, M., Fan, J.-B., Duan, L.,
Glass, C.K., Rosenfeld, M.G., and Fu, X.-D. (2007). Sensitive ChIP-
DSL technology reveals an extensive ERa binding program on human
gene promoters. Proc. Natl. Acad. Sci. USA, in press. 10.1073/PNAS.
0700715104.
Lachner, M., and Jenuwein, T. (2002). Themany faces of histone lysine
methylation. Curr. Opin. Cell Biol. 14, 286–298.
Lee, M.G., Wynder, C., Cooch, N., and Shiekhattar, R. (2005). An es-
sential role for CoREST in nucleosomal histone 3 lysine 4 demethyla-
tion. Nature 437, 432–435.
Li, J., Lin, Q., Yoon, H.G., Huang, Z.Q., Strahl, B.D., Allis, C.D., and
Wong, J. (2002). Involvement of histone methylation and phosphoryla-
tion in regulation of transcription by thyroid hormone receptor. Mol.
Cell. Biol. 22, 5688–5697.
Lunyak, V.V., Burgess, R., Prefontaine, G.G., Nelson, C., Sze, S.H.,
Chenoweth, J., Schwartz, P., Pevzner, P.A., Glass, C., Mandel, G.,
and Rosenfeld, M.G. (2002). Corepressor-dependent silencing of
chromosomal regions encoding neuronal genes. Science 298, 1747–
1752.
Ma, H., Baumann, C.T., Li, H., Strahl, B.D., Rice, R., Jelinek, M.A.,
Aswad, D.W., Allis, C.D., Hager, G.L., and Stallcup, M.R. (2001).
Hormone-dependent, CARM1-directed, arginine-specific methylation
ofhistoneH3onasteroid-regulatedpromoter.Curr.Biol.11, 1981–1985.
Margueron, R., Trojer, P., and Reinberg, D. (2005). The key to develop-
ment: interpreting the histone code? Curr. Opin. Genet. Dev. 15, 163–
176.
Martin, C., and Zhang, Y. (2005). The diverse functions of histone lysine
methylation. Nat. Rev. Mol. Cell Biol. 6, 838–849.
McKenna, N.J., and O’Malley, B.W. (2002). Combinatorial control of
gene expression by nuclear receptors and coregulators. Cell 108,
465–474.
McKinsey, T.A., Zhang, C.L., and Olson, E.N. (2001). Control of muscle
development by dueling HATs and HDACs. Curr. Opin. Genet. Dev. 11,
497–504.
Metivier, R., Penot, G., Carmouche, R.P., Hubner, M.R., Reid, G.,
Denger, S., Manu, D., Brand, H., Kos, M., Benes, V., and Gannon, F.
(2004). Transcriptional complexes engaged by apo-estrogen recep-
tor-alpha isoforms have divergent outcomes. EMBO J. 23, 3653–3666.
Metzger, E., Wissmann, M., Yin, N., Muller, J.M., Schneider, R., Peters,
A.H., Gunther, T., Buettner, R., and Schule, R. (2005). LSD1 demethy-
lates repressive histone marks to promote androgen-receptor-depen-
dent transcription. Nature 437, 436–439.
Nakamura, T., Mori, T., Tada, S., Krajewski, W., Rozovskaia, T.,
Wassell, R., Dubois, G., Mazo, A., Croce, C.M., and Canaani, E.
(2002). ALL-1 is a histone methyltransferase that assembles a super-
complex of proteins involved in transcriptional regulation. Mol. Cell
10, 1119–1128.
Narlikar, G.J., Fan, H.Y., and Kingston, R.E. (2002). Cooperation be-
tween complexes that regulate chromatin structure and transcription.
Cell 108, 475–487.
Nazareth, L.V., andWeigel, N.L. (1996). Activation of the human andro-
gen receptor through a protein kinase A signaling pathway. J. Biol.
Chem. 271, 19900–19907.
Nielsen, S.J., Schneider, R., Bauer, U.M., Bannister, A.J., Morrison, A.,
O’Carroll, D., Firestein, R., Cleary, M., Jenuwein, T., Herrera, R.E., andCell 128, 505–518, February 9, 2007 ª2007 Elsevier Inc. 517
Kouzarides, T. (2001). Rb targets histone H3 methylation and HP1 to
promoters. Nature 412, 561–565.
Ogawa, H., Ishiguro, K., Gaubatz, S., Livingston, D.M., and Nakatani,
Y. (2002). A complex with chromatin modifiers that occupies E2F-
and Myc-responsive genes in G0 cells. Science 296, 1132–1136.
Ogawa, S., Lozach, J., Jepsen, K., Sawka-Verheller, D., Perissi, V.,
Sasik, R., Rose, D.W., Johnson, R.S., Rosenfeld, M.G., and Glass,
C.K. (2004). A nuclear receptor corepressor transcriptional checkpoint
controlling activator protein 1-dependent gene networks required for
macrophage activation. Proc. Natl. Acad. Sci. USA 101, 14461–14466.
Perissi, V., Aggarwal, A., Glass, C.K., Rose, D.W., and Rosenfeld, M.G.
(2004). A corepressor/coactivator exchange complex required for
transcriptional activation by nuclear receptors and other regulated
transcription factors. Cell 116, 511–526.
Peterson, C.L., and Laniel, M.A. (2004). Histones and histonemodifica-
tions. Curr. Biol. 14, R546–R551.
Privalsky, M.L. (2004). The role of corepressors in transcriptional
regulation by nuclear hormone receptors. Annu. Rev. Physiol. 66,
315–360.
Rogatsky, I., Trowbridge, J.M., and Garabedian, M.J. (1999). Potenti-
ation of human estrogen receptor alpha transcriptional activation
through phosphorylation of serines 104 and 106 by the cyclin A-
CDK2 complex. J. Biol. Chem. 274, 22296–22302.
Rosenfeld, M.G., Lunyak, V.V., and Glass, C.K. (2006). Sensors and
signals: a coactivator/corepressor/epigenetic code for integrating sig-
nal-dependent programs of transcriptional response. Genes Dev. 20,
1405–1428.
Saccani, S., and Natoli, G. (2002). Dynamic changes in histone H3 Lys
9 methylation occurring at tightly regulated inducible inflammatory
genes. Genes Dev. 16, 2219–2224.
Schultz, D.C., Ayyanathan, K., Negorev, D., Maul, G.G., and Rauscher,
F.J., 3rd. (2002). SETDB1: a novel KAP-1-associated histone H3, lysine
9-specific methyltransferase that contributes to HP1-mediated silenc-
ing of euchromatic genes by KRAB zinc-finger proteins. Genes Dev.
16, 919–932.
Shi, Y., Sawada, J., Sui, G., Affar, el B., Whetstine, J.R., Lan, F.,
Ogawa, H., Luke, M.P., Nakatani, Y., and Shi, Y. (2003). Coordinated
histone modifications mediated by a CtBP co-repressor complex. Na-
ture 422, 735–738.
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J.R., Cole, P.A.,
Casero, R.A., and Shi, Y. (2004). Histone demethylation mediated by
the nuclear amine oxidase homolog LSD1. Cell 119, 941–953.
Shi, Y.J., Matson, C., Lan, F., Iwase, S., Baba, T., and Shi, Y. (2005).
Regulation of LSD1 histone demethylase activity by its associated fac-
tors. Mol. Cell 19, 857–864.
Strahl, B.D., and Allis, C.D. (2000). The language of covalent histone
modifications. Nature 403, 41–45.
Steele-Perkins, G., Fang, W., Yang, X.H., Van Gele, M., Carling, T., Gu,
J., Buyse, I.M., Fletcher, J.A., Liu, J., Bronson, R., et al. (2001). Tumor
formation and inactivation of RIZ1, an Rb-binding member of a nuclear
protein-methyltransferase superfamily. Genes Dev. 15, 2250–2262.518 Cell 128, 505–518, February 9, 2007 ª2007 Elsevier Inc.Tong, J.K., Hassig, C.A., Schnitzler, G.R., Kingston, R.E., and
Schreiber, S.L. (1998). Chromatin deacetylation by an ATP-dependent
nucleosome remodelling complex. Nature 395, 917–921.
Trewick, S.C., McLaughlin, P.J., and Allshire, R.C. (2005). Methylation:
lost in hydroxylation? EMBO Rep. 6, 315–320.
Tsukada,Y., Fang, J., Erdjument-Bromage,H.,Warren,M.E.,Borchers,
C.H., Tempst, P., and Zhang, Y. (2006). Histone demethylation by a
family of JmjC domain-containing proteins. Nature 439, 811–816.
Ueda, T., Mawji, N.R., Bruchovsky, N., and Sadar, M.D. (2002). Ligand-
independent activation of the androgen receptor by IL-6 and the role of
the coactivator SRC-1 in prostate cancer cells. J. Biol. Chem. 277,
38087–38094.
Wang, H., An, W., Cao, R., Xia, L., Erdjument-Bromage, H., Chatton,
B., Tempst, P., Roeder, R.G., and Zhang, Y. (2003). mAM facilitates
conversion by ESET of dimethyl to trimethyl lysine 9 of histone H3 to
cause transcriptional repression. Mol. Cell 12, 475–487.
Whetstine, J.R., Nottke, A., Lan, F., Huarte, M., Smolikov, S., Chen, Z.,
Spooner, E., Li, E., Zhang, G., Colaiacovo, M., and Shi, Y. (2006). Re-
versal of histone lysine trimethylation by the JMJD2 family of histone
demethylase. Cell 125, 467–481.
Wysocka, J., Swigut, T., Milne, T.A., Dou, Y., Zhang, X., Burlingame,
A.L., Roeder, R.G., Brivanlou, A.H., and Allis, C.D. (2005). WDR5 asso-
ciates with histone H3 methylated at K4 and is essential for H3 K4
methylation and vertebrate development. Cell 121, 859–872.
Yamane, K., Toumazou, C., Tsukada, Y., Erdjument-Bromage, H.,
Tempst, P., Wong, J., and Zhang, Y. (2006). JHDM2A, a JmjC-contain-
ing H3K9 demethylase, facilitates transcription activation by androgen
receptor. Cell 125, 483–495.
Yang, L., Xia, L., Wu, D.Y., Wang, H., Chansky, H.A., Schubach, W.H.,
Hickstein, D.D., and Zhang, Y. (2002). Molecular cloning of ESET,
a novel histone H3-specific methyltransferase that interacts with
ERG transcription factor. Oncogene 21, 148–152.
Yang, X.J., and Seto, E. (2003). Collaborative spirit of histone deacety-
lases in regulating chromatin structure and gene expression. Curr.
Opin. Genet. Dev. 13, 143–153.
You, A., Tong, J.K., Grozinger, C.M., and Schreiber, S.L. (2001).
CoREST is an integral component of the CoREST- human histone
deacetylase complex. Proc. Natl. Acad. Sci. USA 98, 1454–1458.
Zhang, C.L., McKinsey, T.A., and Olson, E.N. (2002). Association of
class II histone deacetylases with heterochromatin protein 1: potential
role for histone methylation in control of muscle differentiation. Mol.
Cell. Biol. 22, 7302–7312.
Zhu, P., Baek, S.H., Bourk, E.M., Ohgi, K.A., Garcia-Bassets, I., Sanjo,
H., Akira, S., Kotol, P.F., Glass, C.K., Rosenfeld, M.G., and Rose, D.W.
(2006). Macrophage/cancer cell interactions mediate hormone resis-
tance by a nuclear receptor derepression pathway. Cell 124, 615–629.
Zwijsen, R.M., Wientjens, E., Klompmaker, R., van der Sman, J.,
Bernards, R., and Michalides, R.J. (1997). CDK-independent activa-
tion of estrogen receptor by cyclin D1. Cell 88, 405–415.
